WO2014102755A4 - Formulations de bortézomib - Google Patents

Formulations de bortézomib Download PDF

Info

Publication number
WO2014102755A4
WO2014102755A4 PCT/IB2013/061430 IB2013061430W WO2014102755A4 WO 2014102755 A4 WO2014102755 A4 WO 2014102755A4 IB 2013061430 W IB2013061430 W IB 2013061430W WO 2014102755 A4 WO2014102755 A4 WO 2014102755A4
Authority
WO
WIPO (PCT)
Prior art keywords
bortezomib
lyophilized composition
composition according
solution
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/061430
Other languages
English (en)
Other versions
WO2014102755A1 (fr
Inventor
Pradeep SHIVAKUMAR
Shivamurthy RAMAKRISHNAIAH
Badrinath ALAMPALLI
Akshaykant CHATURVEDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shilpa Medicare Ltd
Original Assignee
Shilpa Medicare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shilpa Medicare Ltd filed Critical Shilpa Medicare Ltd
Priority claimed from IN5769CH2013 external-priority patent/IN2013CH05769A/en
Publication of WO2014102755A1 publication Critical patent/WO2014102755A1/fr
Publication of WO2014102755A4 publication Critical patent/WO2014102755A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques de Bortézomib et ses procédés de préparation.
PCT/IB2013/061430 2012-12-31 2013-12-31 Formulations de bortézomib Ceased WO2014102755A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN5517/CHE/2012 2012-12-31
IN5517CH2012 2012-12-31
IN5769/CHE/2013 2013-12-13
IN5769CH2013 IN2013CH05769A (fr) 2013-12-13 2013-12-31

Publications (2)

Publication Number Publication Date
WO2014102755A1 WO2014102755A1 (fr) 2014-07-03
WO2014102755A4 true WO2014102755A4 (fr) 2014-08-21

Family

ID=51019977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061430 Ceased WO2014102755A1 (fr) 2012-12-31 2013-12-31 Formulations de bortézomib

Country Status (1)

Country Link
WO (1) WO2014102755A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016059515A1 (fr) * 2014-10-18 2016-04-21 Shilpa Medicare Limited Formulations de bortézomib
US20190290718A1 (en) * 2015-08-06 2019-09-26 Ftf Pharma Private Limited Composition comprising bortezomib
EA038105B1 (ru) * 2018-06-13 2021-07-07 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бортезомиб, продукт способа

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR20100051828A (ko) * 2007-09-12 2010-05-18 닥터 레디스 레보러터리즈 리미티드 보르테조밉 및 그의 제조방법
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
EP2238973A1 (fr) * 2009-04-07 2010-10-13 Cephalon France Préparations lyophilisées d'inhibiteurs du protéasome
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2012131707A2 (fr) * 2011-03-28 2012-10-04 Laurus Labs Private Limited Nouvelle forme cristalline de bortezomib, son procédé de préparation et composition pharmaceutique l'utilisant

Also Published As

Publication number Publication date
WO2014102755A1 (fr) 2014-07-03

Similar Documents

Publication Publication Date Title
JP2018109005A (ja) ベンダムスチン製剤
WO2008024435A3 (fr) Transporteurs intracellulaires moléculaires dendritiques et leurs procédés de fabrication et d'utilisation
MX2010004244A (es) Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk).
TNSN08475A1 (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
WO2014102755A4 (fr) Formulations de bortézomib
US20200306266A1 (en) Solid dispersion of dutasteride, method for producing same, and pharmaceutical composition comprising same
EP1898884A2 (fr) Procede de fabrication de tigecycline
CN103087079B (zh) 一种哌拉西林的结晶方法
CN102860980B (zh) 一种罗库溴铵注射液的制备方法
CN104892909B (zh) 一种聚乙二醇单甲醚‑聚乳酸嵌段共聚物的制备方法
CN102302462B (zh) 一种盐酸吉西他滨冻干制剂
CN103110597B (zh) 盐酸厄洛替尼片及其制备方法
WO2010080339A4 (fr) Compositions de phényléphrine à stabilité améliorée
CN105534943A (zh) 一种他克莫司速释制剂及其制备方法
WO2011144650A1 (fr) Compositions aqueuses pharmaceutiques comprenant de l'acide lipoïque en tant qu'anti-oxydant
AU2011254651A1 (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
WO2014198342A1 (fr) Composition pharmaceutique comprenant du sunitinib amorphe
CN104208077A (zh) 注射用脂溶性维生素药物组合物及其制备方法
WO2010092446A1 (fr) Composition pharmaceutique comprenant de la cilastatine, un agent de chélation et optionnellement un antibiotique de type pénème
Mishra et al. Solubility enhancement of clarithromycin using solid dispersion and effervescence assisted fusion technique
CA2534259A1 (fr) Preparation ayant une concentration elevee en glycyrrhizine
CN101669956B (zh) 一种头孢西丁酸的组合物
EP3173075B1 (fr) Préparation pharmaceutique combinée constituée d'un inhibiteur ace et diurétique de l'anse
CN101491495A (zh) 丹酚酸b镁注射剂、制备方法及应用
CN102920716B (zh) 复方抗球虫药物磺胺氯吡嗪钠溶液的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13867963

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 13867963

Country of ref document: EP

Kind code of ref document: A1